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Abstract
Recent studies have identified thousands of regions in the genome associated with chroma-
tin modifications, which may in turn be affecting gene expression. Existing works have used
heuristic methods to investigate the relationships between genome, epigenome, and gene
expression, but, to our knowledge, none have explicitly modeled the chain of causality
whereby genetic variants impact chromatin, which impacts gene expression. In this work we
introduce a new hierarchical fine-mapping framework that integrates information across all
three levels of data to better identify the causal variant and chromatin mark that are concor-
dantly influencing gene expression. In simulations we show that our method is more accu-
rate than existing approaches at identifying the causal mark influencing expression. We
analyze empirical genetic, chromatin, and gene expression data from 65 African-ancestry
and 47 European-ancestry individuals and show that many of the paths prioritized by our
method are consistent with the proposed causal model and often lie in likely functional
regions.
Author summary
Genome-wide association studies (GWAS) have revealed that the majority of variants
associated with complex disease lie in noncoding regulatory sequences. More recent stud-
ies have identified thousands of quantitative trait loci (QTLs) associated with chromatin
modifications, which in turn are associated with changes in gene regulation. Thus, one
proposed mechanism by which genetic variants act on trait is through chromatin, which
may in turn have downstream effects on transcription. In this work, we propose a method
that assumes a causal path from genetic variation to chromatin to expression and inte-
grates information across all three levels of data in order to identify the causal variant and
chromatin mark that are likely influencing gene expression. We demonstrate in simula-
tions that our probabilistic approach produces well-calibrated posterior probabilities and
outperforms existing methods with respect to SNP-, mark-, and overall path-mapping.
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Introduction
Discerning the genetic and molecular basis of complex traits is a fundamental problem in biol-
ogy. Genome-wide association studies have revealed that the majority of variants associated
with disease lie in noncoding regulatory sequences [1, 2]. Identifying the target genes of these
variants and the mechanisms through which they act remains an open problem [3]. Recent
efforts to systematically characterize how genetic variation impacts more granular molecular
phenotypes have yielded thousands of single nucleotide polymorphisms (SNPs) that associate
with local and distal histone modifications—termed histone quantitative trait loci (hQTLs) [4–
7]. Furthermore, recent studies have identified many expression quantitative trait loci (eQTLs)
that co-localize with hQTLs, implying there may exist a shared genetic influence on epigenetic
traits and gene expression [8–11]. Therefore, one proposed mechanism by which regulatory
variants may affect gene expression and thereby impact traits is through changes in chromatin
state [10]. However, this putative chain of causality whereby the effects of SNPs on expression
are mediated by chromatin modifications has yet to be established. This is further com-
pounded by the complex space of plausible causal directions connecting transcription factor
binding, DNA methylation, chromatin variation, and gene expression. Since laboratory experi-
ments are very costly, there is a need for statistical methods that can accurately prioritize the
causal SNP and chromatin mark within an implicated region under a plausible causal model.
However, even if the causal direction is given, pinpointing the exact SNP and mark within a
genomic region is very challenging due to the confounding effects of linkage disequilibrium
(LD) among SNPs and correlations among marks [5, 6, 10, 12–14].
Methods to investigate the relationships between the genome, the epigenome, and expres-
sion have largely focused on quantifying the overlap between hQTLs and eQTLs [10, 14, 15].
Previous studies have sought to identify hQTLs by selecting the SNP with the strongest p-value
for association to a local chromatin mark and to local gene expression [10, 14, 15]. Moreover,
various methods exist for the fine-mapping of SNPs that may be concurrently affecting two
traits, including eCAVIAR [16] and Coloc [17]. Although these methods can be applied to
jointly analyze SNP, chromatin, and expression data, they do not model the causal path
whereby SNPs impact expression through chromatin alteration.
Here we propose a fine-mapping framework, pathfinder, that explicitly models the hierar-
chical relationships between genome, chromatin, and gene expression to predict both the
causal SNP and the causal mark within a gene region that are influencing expression of a given
gene. Our framework assumes a causal model where a SNP impacts a chromatin which in turn
alters gene expression. In our framework we refer to a “causal” SNP as any SNP that disrupts
inter-individual variation of chromatin state either through a direct biological mechanism
(e.g., chromatin accessibility) or indirectly through an unobserved biological mechanism. Sim-
ilarly, we refer to a “causal” chromatin mark as either a mark that biologically alters expression
or that tags an underlying epigenetic regulatory mechanism of expression. Our framework
takes as input the strength of association (as quantified through the standard Z-scores)
between all SNP/mark pairs and all marks to expression as measured in a given set of individu-
als. To explicitly account for the correlation structure among SNPs and marks, we use a
Matrix-variate Normal distribution to model all Z-scores jointly. By construction, this allows
our probabilistic model to assign posterior probabilities for each SNP, mark, and path (where
paths include all possible SNP-mark combinations) to be causal in the region. A key advantage
of our approach is that it produces well-calibrated posterior probabilities for causality. Thus,
pathfinder can be used to prioritize variants and marks for validation experiments.
In simulations we compare against several existing methods, demonstrating that path-
finder outperforms alternative approaches with respect to both accuracy and calibration.
Methods for fine-mapping with chromatin and expression data
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This is largely because our comparators do not take into account mark-expression associa-
tions. In some cases, these additional associations may help distinguish between two poten-
tially causal paths that have comparable evidence for causality. For example, in cases where a
SNP is associated with expression of a local gene and is also associated with two local chro-
matin marks, knowledge of the impact of each mark on gene expression may help distin-
guish between two possible paths for causality. Finally, we analyze genotype, chromatin and
expression data from 65 African-ancestry and 47 European-ancestry individuals. We show
that the top causal SNPs proposed by pathfinder tend to lie in more functional regions and
disturb more regulatory motifs than expected by chance. We also present evidence that most
of the top paths reported by pathfinder demonstrate consistency with our proposed sequen-
tial model, thus strengthening the case for our method’s applicability to empirical biological
data.
Results
Overview of hierarchical fine-mapping with genetic, chromatin, and gene
expression data
Here we introduce a hierarchical statistical method for fine-mapping of causal SNPs and chro-
matin marks (e.g., histone modifications) that may be concordantly influencing gene expres-
sion within a genomic region. We build upon previous insights that a vector of Z-scores is
well-described by a Multivariate Normal (MVN) distribution parameterized by LD [13, 18, 19]
to model association statistics between chromatin marks and gene expression. We analyze all
chromatin peaks across four mark types (DHS, H3K4me1, H3K4me3, and H3K27ac) jointly in
the same framework; we refer to a “mark” as a chromatin peak at a particular location, and
“mark types” as DHS, H3K4me1, H3K4me3, and H3K27ac. To simultaneously take into
account both SNP LD and the correlations between chromatin marks, we use the Matrix-vari-
ate Normal distribution to jointly model association statistics between all SNPs and marks
within a region. Our method takes as input SNP-mark and mark-expression associations
within a region centered around a particular gene, as well as correlations among all SNPs (LD)
and correlations among all considered marks. Pathfinder enumerates over all possible causal
paths, considering one causal SNP and one causal mark for each path, and outputs a posterior
probability for each path to be causal, which can subsequently be used to prioritize SNPs and
marks for validation. We compute marginal probabilities for individual SNPs (or marks) to be
causal by summing the posterior probabilities over all paths that contain the SNP (or mark).
For simplicity, in this work we refer to a “causal” mark as a mark that either causally drives
inter-individual variation of gene expression or is correlated to an underlying causal mecha-
nism (e.g. transcription factor binding), though it may not be biologically causal for
expression.
The advantage of our method over existing approaches is that it integrates mark-expression
associations which may help distinguish between two paths with otherwise comparable evi-
dence for causality. We illustrate a scenario in Fig 1. Consider a genetic region where SNP g1
has a strong association with two local marks h1 and h2, as well as a significant association with
gene expression. Using only SNP-mark and SNP-expression effects, we are unable to discern
whether SNP g1 influences expression through mark h1 or h2. However, if we consider mark-
expression effects, we see that mark h1 has a strong association with gene expression where
mark h2 does not. This additional information helps support the hypothesis that there is a
causal path from SNP g1 to mark h1 to gene expression.
Methods for fine-mapping with chromatin and expression data
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Pathfinder improves fine-mapping performance
We used simulations to compare pathfinder’s performance against alternative methods with
respect to SNP-, mark-, and path-finding efficiency as well as the calibration of its posterior
probabilities. We generated genetic, chromatin, and gene expression data for 10,000 50kb
regions, each centered around a single gene, over 100 individuals, using SNP LD and mark
correlations derived from 65 Yoruban (YRI) individuals (see Methods). We define a “mark” as
an individual peak location for any mark type in the dataset (DHS, H3M4me1, H3K4me3, or
H3K27ac). For each gene, we randomly assigned a single causal pathway from one SNP to one
mark to gene expression. We then ran our methods on all regions individually and assessed
their ability to correctly prioritize the true causal path in each region (Methods).
We compare against an independent fine-mapping approach (whereby we fine-map SNP-
mark associations and mark-expression associations independently and take the product of
the resulting probabilities to produce posterior probabilities for paths), a Bayesian network
analysis [20], a naive ranking (where we rank SNP-expression and mark-expression associa-
tions to prioritize SNPs and marks within a region; for path-finding, we rank the product of
these two), a formal colocalization method [17], and finally, against overlaps between eQTLs
and hQTLs within a region centered around a gene of interest (see Methods). Unlike the first
four approaches, the overlap methods do not produce rankings, but yield candidate sets of
causal SNPs, marks, and paths. For this reason, we present these results in a separate analysis
using an alternative metric for comparison.
We find that pathfinder has consistently better performance than the other ranking
approaches with respect to all three features—SNP-, mark-, and path-mapping within a region
(Fig 2). For example, association ranking, Coloc, Bayesian network analysis, and independent
fine-mapping accumulate 55%, 62%, 47%, and 13% of the top paths on average in order to
recapture 90% of the causal paths, whereas our method only requires 8% of the top paths.
Note that SNP-expression association ranking is equivalent to running a basic eQTL analysis,
which does not take into account chromatin data, in order to identify causal SNPs. A similar
improvement in accuracy was observed for the size of the credible sets, defined as the number
of SNPs required to capture a given percentage of the causal variants (S1 Table).
Fig 1. Schematic of hierarchical model whereby SNPs affect histone marks, which in turn affect gene expression. We illustrate a scenario
where SNP g1 and mark h1 are causal. All other induced correlations, such as the effect of g1 on h2, are an effect of LD and/or correlations among
marks. To the right we show our mathematical model for this hierarchical framework. On the top level, we model mark-expression associations
with a Multivariate Normal (MVN) distribution. On the bottom, we jointly model all associations between all SNPs and marks with a Matrix
Variate Normal distribution (see Methods).
https://doi.org/10.1371/journal.pgen.1007240.g001
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Next, we evaluated pathfinder’s performance compared against standard analyses that
investigate overlaps between hQTLs and eQTLs within a genomic region. In such experiments,
the variant with the strongest association to each local chromatin mark is selected, as well as
the variant with the strongest association to local gene expression. In addition, marks are fil-
tered to ensure a 10% FDR (see Methods). This produces a set of candidate marks, as well as
one candidate SNP per mark, and one SNP deemed causal for gene expression in the region.
Implicitly, the overlap of these variants suggests a set of candidate SNPs, marks, and paths for
the region. For the same set sizes, pathfinder identifies 96% of the causal marks versus 74% in
the standard overlap approach (Fig 3). SNP-finding accuracy is comparable between the two
methods.
We next assessed the calibration of the posterior probabilities for causality output by path-
finder. Our method has slightly deflated credible sets for SNP- and path-finding, but well-cali-
brated credible sets for mark-finding (Fig 4). In contrast, the independent fine-mapping
approach has consistently inflated credible sets—that is, it captures more causal paths than
expected, but also has drastically larger credible set sizes. For example, when accumulating
90% of the posterior probabilities over all regions, pathfinder captures 88% of the true causal
paths within the top 380 candidate paths, whereas independent fine-mapping captures 94% of
the causal paths within the top 1026 candidate paths. Similar outcomes were attained for the
50% and 99% credible sets (S1 Fig). Overall, pathfinder’s credible sets are less biased and nar-
rower than those obtained through the independent fine-mapping approach.
Finally, we investigated the effects of simulation and method parameters on pathfinder’s
accuracy. Firstly, we varied the causal SNP and mark effect sizes such that the variance
explained of mark and gene expression ranged from 0.1 to 0.5. As anticipated, increased heri-
tability leads to better performance (See Fig 5A–5C). Secondly, in order to assess the impact of
SNP LD and mark correlations on SNP- and mark-finding performance, we stratified our
existing simulations based on the mean correlation of the causal SNP or mark to all other
SNPs or marks (See Fig 5D–5I). We grouped our simulations into three categories: low,
medium, and high correlations. As anticipated, SNP-finding performance decreases slightly as
SNP LD increases. Notably, mark-finding performance is actually improved at higher SNP
LD. This is due to the redundancy in information about SNP-mark associations at the causal
mark when these effects are exhibited across multiple correlated SNPs. SNP- and mark-finding
Fig 2. Comparison of our method against four potential competitors—Independent fine-mapping, a simple ranking of associations,
Coloc, and Bayesian network analysis. We measure performance as the number of simulated causal SNPs, marks, and paths that each method
is able to recapture, while varying the number of SNPs, marks, or paths considered.
https://doi.org/10.1371/journal.pgen.1007240.g002
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performance, however, do not seem to be significantly affected by mark correlations in our
simulations—at least not at the level of variation exhibited in our data. In addition to stratify-
ing our existing simulations by LD, we also assessed the impact of using European rather than
African LD in the same regions, as European LD is known to be more extensive. Here we
retained the YRI mark and expression data in order to isolate the effect of SNP correlations.
The credible set sizes computed from the CEU dataset do not substantially differ from those
obtained in YRI (S2 Table). This result demonstrates that the more extensive LD observed in
European individuals will not significantly affect pathfinder’s performance. Thirdly, we
Fig 3. Comparison of our method to standard eQTL + hQTL overlap analyses. In overlap analyses, only the top SNP for association to each
histone mark and gene expression is considered. We demonstrate significant gains in our method with respect to mark-finding accuracy, where
SNP-mapping performance is comparable between the two methods.
https://doi.org/10.1371/journal.pgen.1007240.g003
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evaluated the effect of the prior variance tuning parameter on fine-mapping performance (See
Fig 5J–5L). The prior variance is an estimate of the variance explained by the causal SNP and
mark in the region, as we do not know a priori what the causal effect sizes are. We show that
the optimal range for the prior variance parameters is between 5 and 10, in simulations with a
variance explained of 0.25 on both levels. Overall, performance does not seem to change drasti-
cally in response to variations in the prior variance, even significantly outside of this optimal
range.
Violations of the model
Our hierarchical model makes several key assumptions that may sometimes be violated in
empirical data. Firstly, pathfinder assumes that a single causal SNP and a single causal mark
are driving the associations within a region, where in reality there may exist multiple true
causal SNPs or marks [13, 19]. Secondly, pathfinder assumes that SNP effects on gene expres-
sion are mediated by a chromatin mark, which may not be the case in real data. We therefore
assessed the performance of our method when these two assumptions are violated in various
ways, diagrammed in Fig 6.
First, we investigate violations 1–3, which include multiple causal pathways throughout the
region. Path-mapping accuracy, measured by the proportion of causal paths identified, is
reduced in all three scenarios (Fig 6). Note that the number of causals identified does not nec-
essarily decrease, but rather the proportion, as there are more causal paths in each region.
SNP- and mark-finding accuracy under these violations are also compromised, but with two
notable exceptions. In the multi-causal-SNP scenario, mark-finding accuracy increased in
comparison with the single-SNP simulations; for example, only 8% of marks were selected
(versus 18% in the single causal simulations) to capture 90% of the causal marks. In the multi-
Fig 4. 90% credible sets for SNP-, mark-, and path-mapping. We compare pathfinder to the technique of independently fine-mapping the two
levels of data, with respect to (A) the calibration of their credible sets and (B) the size of their credible sets. In (A), we compare the proportion of
causal variants that were captured in the 90% credible sets using pathfinder vs. independent fine-mapping against the expected proportion
(represented by the dotted line). In (B), we display the corresponding sizes of these credible sets.
https://doi.org/10.1371/journal.pgen.1007240.g004
Methods for fine-mapping with chromatin and expression data
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Fig 5. Performance of our method as we vary levels of variance explained, SNP LD, mark correlations, and the prior
variance parameter. (A-C) We simultaneously vary the variance explained by SNP and mark from 0.1 to 0.5 per region.
(D-I) We stratified based on mean SNP/mark correlations at the causal SNP/mark. (J-L) We show that pathfinder is not
sensitive to variations in our prior variance parameter.
https://doi.org/10.1371/journal.pgen.1007240.g005
Methods for fine-mapping with chromatin and expression data
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causal-mark scenario, SNP-finding accuracy increased. Intuitively, this is due to the redun-
dancy in the signal that is captured by the Matrix-variate Normal distribution.
We next investigate violations 4–5, in which an additional SNP or mark influences gene
expression directly. We observe in these two scenarios that performance is reduced for SNP-,
mark-, and path-finding, but not drastically. For example, in order to capture 90% of the causal
paths, pathfinder must select on average 25% and 28% of paths under violations 4 and 5,
respectively (compared with 15% under standard simulations). Because anti-correlated marks
(e.g. activating and repressing marks) often tend to act in the same region, we also assess path-
finder’s behavior specifically when two marks have opposite effects on expression. As expected,
pathfinder’s performance does not decline in the presence of anti-correlated peaks (S2 Fig).
Finally, we discuss pathfinder’s performance under violations where the causal order is
modified (violations 6–7). Under violation 6, where a single causal SNP affects gene expression
directly, which in turn affects a single mark, pathfinder actually captures a higher proportion
of the affected marks and overall paths. For example, in order to capture 90% of the causal
paths, pathfinder must select on average only 3% of the top-ranked paths (compared with 15%
under standard simulations). In violation 7, where the SNP has independent effects on the
mark and the gene expression, we show that pathfinder’s accuracy in finding the causal mark
and path is significantly reduced. Note that in this case, the “path” is not truly a path but a
Fig 6. Performance of our method under violations of the causal model. (A-C) pathfinder’s SNP-, mark-, and path-mapping accuracy for
standard simulations compared with seven model violations. (D) The model violations include the following scenarios: (1) multiple causal SNPs
impact a single causal mark, which affects gene expression, (2) a single SNP impacts multiple causal marks, which both affect gene expression, (3)
two SNPs affect two marks (respectively), which both impact gene expression, (4) a single causal SNP impacts a single causal mark that affects
gene expression, with an additional SNP also impacting gene expression directly, (5) a single causal SNP impacts a single causal mark that affects
gene expression, with an additional mark also impacting gene expression, (6) a single causal SNP affects gene expression directly, which in turn
affects a single mark, and (7) a single causal SNP has independent effects on a single mark and gene expression.
https://doi.org/10.1371/journal.pgen.1007240.g006
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SNP/mark pair, as effects of the SNP on mark and gene expression are independent. Our
power in distinguishing between these two models depends on the prior variance explained
parameter. Under violation 7, the variance explained in gene expression by the causal mark is
much smaller than expected, thus reducing our confidence in the true causal configuration.
We conclude that under the SNP!expression!mark violation, pathfinder will identify causal
paths very confidently even if they do not follow the assumed SNP!mark!expression model.
Therefore a high posterior probability for a path may not be sufficient evidence for causality.
On the other hand, when SNP effects on mark and expression are independent, pathfinder is
less likely to produce false positives. For these reasons, we recommend a pre- or post-filtering
step to retain only those regions that show some prior evidence for the SNP!mark!expres-
sion model using a conditional analysis or partial correlation approach (Methods).
For completeness, we also assess existing methods under these simulations (S3 Fig). Most
notably, the simple association-ranking approach shows a distinct improvement under viola-
tions 6 and 7, in which SNPs have a direct effect on gene expression. This is expected as path-
finder assumes the causal effect to be mediated by chromatin. A similar improvement can be
observed for Coloc under violation 7, in which the SNP affects both chromatin and gene
expression directly.
Empirical data analyses
We evaluated the behavior of our hierarchical fine-mapping method when applied to empirical
data. We performed these analyses on data from 65 YRI individuals whose genotypes were
obtained through 1000 Genomes, and whose PEER-corrected H3K4me1, H3K4me3,
H3K27ac, DHS, and RNA expression levels in lymphoblastoid cell lines (LCLs) were obtained
from [10]. In each region, we analyzed all four mark types jointly (H3K4me1, H3K4me3,
H3K27ac, and DHS) by including all peaks spanning the region for each mark type. Each peak
of each mark type was therefore treated as a single chromatin mark. We filtered the 14,669
regions using a two-step regression analysis to yield 1,317 regions that showed evidence for the
sequential model of SNPs affecting histone marks which in turn affect gene expression (see
Methods). pathfinder’s runtime scales approximately as s3t3, where s and t are the number of
SNPs and marks within a region, respectively. On average, each 50kb region contained 160
SNPs and 25 marks. Most runs were completed in under a few minutes. The most dense region
contained 331 SNPs and 66 marks and took approximately 21 minutes (S4 Fig).
In Table 1, we report the average 50%, 90%, and 99% credible set sizes produced when run-
ning pathfinder on real data. We compare against basic eQTL mapping, where we fine-map
SNPs to gene expression ignoring chromatin data. We show that the credible set sizes are sig-
nificantly narrower when running pathfinder with all three levels of data, consistent with our
findings in simulations. For example, eQTL mapping requires an average of 45.3 SNPs in
order to capture 90% of the posterior probability for SNP causality, whereas pathfinder only
requires 28.4 SNPs. If we define a gene to be fine-mapped if 99% of the posterior probability
mass for SNP causality is contained within the top 10 SNPs or fewer, then standard eQTL
mapping fine-maps 46 of the genes in our data, whereas pathfinder fine-maps 73 of the genes.
Table 1. 50%, 90%, and 99% credible sets for SNP-, mark-, and path-mapping for real data analysis. We compare pathfinder to basic eQTL mapping, with respect to
the size of their credible sets, averaged across all regions. Standard errors are included next to each measurement.
method 50% credible set 90% credible set 99% credible set
SNPs Marks Paths SNPs Marks Paths SNPs Marks Paths
pathfinder 4.9 (0.2) 1.0 (0.0) 7.4 (0.3) 28.4 (1.1) 1.8 (0.1) 158.4 (6.0) 64.2 (2.4) 6.3 (0.2) 765.5 (29.0)
eQTL mapping 8.1 (0.3) - - 45.3 (1.7) - - 92.9 (3.6) - -
https://doi.org/10.1371/journal.pgen.1007240.t001
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Notably, pathfinder also requires only 1.8 marks on average in order to capture 90% of the pos-
terior probability for causal marks. In 82% of the regions where the top two marks capture
more than 90% of the posterior probability, these two marks are two distinct peaks of the same
mark type.
The mean variance explained observed in the top path chosen by pathfinder, across all
conforming regions, were 0.38 (s.e. 0.01) for the SNP-mark effect and 0.20 (s.e. 0.01) for the
mark-expression effect (S5 Fig). These effects are reasonably consistent with the 25% variance
explained we used in simulations at each level (see Simulations). The correlation between the
SNP-mark and mark-expression effect size magnitudes in the top selected paths across all
regions was 0.03 (p = 0.400). That is, the strength of the SNP-mark effect did not seem to cor-
relate with the strength of the mark-expression effect. We assessed the relative impacts of each
type of histone mark by computing the proportion of probability mass assigned to each mark
type in aggregate over all regions (S3 Table). H3K4me3 is the most informative mark type in
this data, capturing 31% of the total probability mass despite being the least prevalent of all
four mark types, constituting only 13% of all marks.
We also report the size of pathfinder’s credible sets when applied to empirical CEU data
rather than YRI in Table 2. These two datasets are not directly comparable, as the types of epi-
genetic marks and their quantities differ substantially. Nonetheless, we demonstrate that path-
finder’s performance on the CEU dataset does not drastically diverge from its behavior in YRI.
Data pre-processing strategies such as PCA and PEER correction may substantially impact the
number of mark-expression correlations that are retained [21]. We find that credible set sizes
for PEER-corrected data are narrower, giving a slight but significant improvement in perfor-
mance (S4 Table).
As our pre-filtering step was designed to preserve only regions in which SNP effects on
gene expression are mediated by chromatin, we expected a large majority of the analyzed
regions to show evidence for this mechanism. To confirm this, we investigated whether the
top paths prioritized by our method demonstrate consistency with this causal model. We
defined a set of top paths as those which were ranked first in a region and whose posterior
probabilities for causality were assigned by pathfinder to be greater than 0.1. This resulted in
480 total top paths. Out of 480 top paths, only 12 had a significant (p< 0.05/480) partial
correlation between SNP and gene expression after controlling for chromatin. However, 193
paths had a significant partial correlation between SNP and chromatin after controlling
for gene expression. This finding suggests that the top paths are more consistent with the
SNP!mark!expression model than with a SNP!expression!mark model.
Next we examined the relationship between the product of the effect sizes between SNP-
mark and mark-expression against the overall SNP-expression association (Fig 7). We expect
this relationship to be correlative; if truly mediated by the mark in question, the overall SNP-
expression effect size should be proportional to the product of the two contributing effect
sizes. Note that we weight our correlation by the reported posterior probability for each path,
such that the paths we have more confidence in will contribute more to this metric. We find a
Table 2. 50%, 90%, and 99% credible sets for SNP-, mark-, and path-mapping for simulations using empirical YRI and CEU data. We compare pathfinder’s perfor-
mance when using SNP LD from YRI vs from CEU, with respect to the size of its credible sets, averaged across all regions. Standard errors are included next to each
measurement.
method 50% credible set 90% credible set 99% credible set
SNPs Marks Paths SNPs Marks Paths SNPs Marks Paths
YRI 4.9 (0.2) 1.0 (0.0) 7.4 (0.3) 28.4 (1.1) 1.8 (0.1) 158.4 (6.0) 64.2 (2.4) 6.3 (0.2) 765.5 (29.0)
CEU 7.4 (0.3) 1.0 (0.0) 10.6 (0.4) 30.1 (1.1) 1.3 (0.0) 90.1 (3.3) 59.5 (2.2) 2.8 (0.1) 269.6 (9.8)
https://doi.org/10.1371/journal.pgen.1007240.t002
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high correlation (r = 0.91) between these effect size vectors for our top paths, as compared
with a correlation of r = 0.36 when running the same analysis on random paths within each
region. This result indicates that pathfinder is identifying many pathways that are likely to be
following its causal model.
In Table 3, we list the top ten paths prioritized by pathfinder across all real data regions.
Most SNPs implicated in these paths are known to alter several regulatory motifs and often lie
in an enhancer region or a promoter region of the genes whose expression they affect. 59%
(s.e. 2%) of the SNPs implicated in the top paths fall into active ChromHMM states (1–7) in
LCLs, including active TSS, flanking active TSS, transcription at gene 5’ and 3’, strong tran-
scription, weak transcription, genic enhancers, and enhancers. Only 47% (s.e. 2%) of random
Fig 7. Relationship between the product of the SNP-mark and mark-expression effect sizes against the overall SNP-expression effect size.
(A) We observe a high correlation (r = 0.91) between these effect size vectors, indicating that our method is identifying many pathways that are
likely to be following our causal model. Here we included only the top paths whose posterior probabilities for causality were assigned to be
greater than 0.1. (B) We show that a significant correlation does not exist for randomly chosen paths.
https://doi.org/10.1371/journal.pgen.1007240.g007
Table 3. Top causal paths produced by real data analysis. For each path, we report the chromosome, the RSID of the implicated SNP, the implicated mark type, the poste-
rior probability we assigned to this path, three Z-scores (SNP to mark association, mark to expression association, SNP to expression association), the GENCODE gene
around which this region was centered, the ChromImpute [24] annotation for the SNP, and the number of regulatory motifs altered by the SNP, as designated by HaploReg
[25].
chr rsid mark type posterior SNP-mark Z mark-exp Z SNP-exp Z gene chromatin state motifs altered
12 rs835044 H3K27ac > 0.99 -13.05 4.97 -4.65 NDUFA12 1TssA 5
1 esv3587154 H3K4me1 > 0.99 -18.13 17.40 -14.97 GSTM1 15Quies -
19 rs385895 H3K4me1 > 0.99 12.60 2.41 1.50 CLC 7Enh 3
15 rs8025332 H3K4me1 > 0.99 -12.07 2.11 -2.35 CELF6 15Quies 1
5 rs1217817 H3K4me1 > 0.99 -14.59 5.58 -4.52 MAP1B 7Enh 4
1 rs7417106 DHS > 0.99 -8.62 -0.16 -0.54 C1orf170 4Tx 22
1 rs111900551 H3K4me3 > 0.99 -8.82 2.26 -2.95 CLCNKA 15Quies 18
3 rs57339700 H3K4me1 > 0.99 -9.66 2.37 -2.29 CAND2 14ReprPCWk 5
6 rs9349050 H3K4me3 > 0.99 -12.47 10.80 -8.19 MDGA1 11BivFlnk 2
3 rs6763025 H3K4me1 > 0.99 10.59 -2.21 -2.18 PRSS50 7Enh 4
https://doi.org/10.1371/journal.pgen.1007240.t003
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paths fall into these active states (p = 0.001834). Moreover, on average, SNPs in the top paths
disturbed 5.35 (s.e. 0.26) regulatory motifs, whereas random SNPs chosen at the same regions
only disturbed 4.40 (s.e. 0.20) motifs on average (p< 0.001). We did not, however, observe a
similar change in transcription factor binding affinity at these motifs (δ = 5.26 vs δ = 5.27,
(p = 0.511)). As an example, in Fig 8A–8D, we display the genomic context for the top region
reported by pathfinder, including average mark signals for DHS, H3K4me1, H3K4me3, and
H3K27ac, stratified by genotype, in a 4kb region centered around the TSS of the NDUFA12
gene. The implicated SNP lies within the NDUFA12 TSS. Fig 8E plots the gene expression sig-
nal against that of the top mark, stratified by genotype. In S6 Fig, we show associations for the
top region reported by pathfinder, spanning a 50kb region centered around the NDUFA12
TSS.
Fig 8. Genomic context of top path reported by pathfinder in real data. (A-D) Mark signals for DHS, H3K4me1, H3K4me3, H3K27ac in a
4kb region centered around the NDUFA12 TSS, stratified by genotype. The implicated SNP, signified by the vertical dotted line, lies 6bp
downstream of the gene TSS, and falls within an H3K27ac peak, which is also the top mark reported by pathfinder. The posterior probability for
causality for this peak was greater than 0.999. (E) Relationship between the H3K27ac peak signal and gene expression, stratified by genotype.
https://doi.org/10.1371/journal.pgen.1007240.g008
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Next we examined the spatial relationships between the SNP, mark, and TSS implicated in
the top paths reported by pathfinder (Fig 9). SNP to mark and mark to TSS distances were sig-
nificantly lower in our selected paths compared with randomly chosen paths at the same
regions. The average distance from SNP to mark in pathfinder’s top paths was approximately
11.7kb, compared to 15.3kb in randomly chosen paths (p< 0.001). The average distance from
mark to TSS in selected paths was approximately 8.6kb, compared to 9.7kb in randomly cho-
sen paths (p = 0.026). SNP to TSS distances were not significantly different in top versus ran-
dom paths (p = 0.108), with top SNPs lying on average 11.7kb away from the TSS and random
SNPs lying 12.4kb away. 5% of top SNPs lied within 2kb of the TSS while 15% lied within 2kb
Fig 9. Spatial relationships between SNP, mark, and TSS in top paths reported by pathfinder vs random paths. (A) Distances from SNP to
mark (B) Distances from mark to TSS (C) Distances from SNP to TSS.
https://doi.org/10.1371/journal.pgen.1007240.g009
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of the corresponding peak. 23% of peaks in the top paths lied within 2kb of the gene TSS. S7
Fig displays all three distances where top paths are stratified by mark type.
To further validate the top paths chosen by pathfinder, we determined the extent to which
SNPs in these paths overlap with eQTLs that have been identified in LCLs using the larger
scale Geuvadis data set [22]. 21% of the top paths contained SNPs that were also identified as
eQTLs from the Geuvadis data set. In comparison, when randomly choosing paths at the same
regions, only 11% overlapped with eQTLs (p< 0.001). Simply choosing the SNP with the high-
est association with gene expression in each region (equivalent to standard eQTL-mapping)
resulted in an overlap of 24% with existing eQTLs. These results contradict the improvement
in accuracy demonstrated in simulations when using pathfinder. We suspect this discrepancy
is due either to imperfect locus ascertainment (i.e., a number of loci may include SNPs that
directly affect gene expression rather than indirectly through chromatin) or the fact that the
Geuvadis eQTLs were also selected using standard fine-mapping approaches and we may thus
expect a stronger agreement between the two resulting eQTL sets.
We also investigated the extent to which pathfinder’s top SNPs overlap with eQTLs that
have been experimentally validated through differential expression in an LCL dataset [23].
Here, we define the set of validated eQTLs to be those whose p-values for differential expres-
sion passed a threshold of 0.01. We find that 2.2% (or 13) of pathfinder’s top SNPs overlap
with this validated set, where choosing the SNP with the highest association with gene expres-
sion in each region resulted in an overlap of 2.3% (also 13 SNPs).
Finally, we investigated whether any of the top paths reported by pathfinder could be found
within GWAS hit regions for various autoimmune diseases, as our data were collected from
LCLs. These autoimmune diseases included Celiac disease, Crohn’s disease, PBC (Primary Bil-
iary Cirrhosis), SLE (Systemic Lupus Erythematosus), MS (Multiple Sclerosis), RA (Rheuma-
toid Arthritis), IBD (Irritable Bowel Disease), and UC (Ulcerative Colitis). We restricted to
GWAS hits with variants associated to the trait with p< 5 × 10−8. We found that 19 of our 480
top paths were contained in a GWAS-implicated region. In Table 4, we report the paths that
localized within autoimmune GWAS regions. In order to determine whether our top paths are
truly enriched in GWAS regions, we established how many of these paths appear in an equiva-
lent number of random regions that have not been implicated by an autoimmune GWAS. We
centered each random region around a SNP that was matched for a similar MAF and LD score
as the GWAS tag SNP. We ran this analysis 100 times to define a null distribution for the num-
ber of top paths found in a background region. We found that 19 out of 480 top paths was not
a significant enrichment (p = 0.44).
Discussion
In this work we proposed a hierarchical fine-mapping framework that integrates three levels of
data—genetic, chromatin, and gene expression—to pinpoint SNPs and chromatin marks that
may be concordantly influencing gene expression. A key contribution of our approach is the
ability to model the correlation structure in the association statistics using a Matrix-variate
Normal distribution. Our approach is superior to existing methods, demonstrating the advan-
tage of using a probabilistic approach that takes into account the full sequential model. More-
over, pathfinder produces well-calibrated posterior probabilities, and is thus a reliable method
for the prioritization of SNPs and marks for functional validation.
We conclude by addressing some of the limitations of our method. Most notably, our
method is based upon the SNP!mark!expression assumption. In many genomic regions that
show simultaneous evidence for SNP to mark and SNP to gene expression effects, this model
will not necessary hold true. In simulations, we show that under the SNP!expression!mark
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violation, pathfinder may identify causal paths very confidently, leading to false positives under
the proposed model. When a SNP is in fact independently influencing a mark and gene expres-
sion, pathfinder is less likely to produce false positives. However, the risk of mis-appropriating
our method in this way can be reduced by requiring genomic regions to show evidence for our
causal model. We recommend a pre-filtering step before running pathfinder on real data that
we outline in Methods. In our empirical data analyses, we demonstrate that this two-step
regression robustly filters out non-conforming regions. We also acknowledge that, though
there are multiple lines of evidence for SNPs influencing expression through local hQTLs,
recent works have also emphasized the importance of interactions with distal hQTLs. Thus,
developing a systematic way to incorporate data in distal regions with evidence for interactions
with a local eQTL would be a fruitful direction. Moreover, pathfinder assumes that the true
causal SNP and mark within a region are present in the data, which may not always be the case.
In this scenario, pathfinder will instead place its confidence in the SNP or mark that best corre-
lates with the missing causal SNP or mark in question. Similarly, many epigenetic marks are
not themselves causal for gene expression, but are simply correlated to a causal event (e.g., tran-
scription factor binding). It is also often the case that multiple marks at promoter and enhancer
regions are concordantly acting to impact gene expression. In these cases, individual marks are
not necessarily causal in themselves, but may be viewed as a cause for inter-individual variation
or simply correlated to a causal factor. In this light, pathfinder aims to identify the epigenetically
modifying region so that it can be tested experimentally and/or characterized functionally (for
example, to identify the effector transcription factor). We also note that pathfinder currently
uses an approximation whereby the observed Z-score at the causal SNP is used to estimate the
true NCP at the causal SNP (Methods). We leave this to be addressed in future work; this
Table 4. Top causal paths reported in real data analysis that localized within GWAS regions for 8 autoimmune diseases. For each path, we report the chromosome,
the RSID of the implicated SNP, the implicated mark type, the posterior probability we assigned to this path, three Z-scores (SNP to mark association, mark to expression
association, SNP to expression association), the GENCODE gene around which this region was centered, the ChromHMM [24] annotation for the SNP, and the number
of regulatory motifs altered by the SNP, as designated by HaploReg [25].
chr rsid GWAS mark type posterior SNP-mark mark-exp SNP-exp gene chrom state motifs altered
2 rs2975781 UC, IBD H3K27ac 1.00 -9.00 5.33 -4.96 GPR35 7Enh 9
8 rs2618481 SLE H3K27ac 0.94 -6.04 6.59 -3.99 BLK 2TssAFlnk 0
16 rs9927129 Crohn’s, IBD H3K4me1 0.66 -7.82 -0.79 1.59 RP11-
1348G14.2
15Quies 1
6 rs2071889 UC, SLE, MS, RA, IBD DHS 0.61 6.51 -3.23 -1.78 TAPBP 4Tx 2
16 rs394502 Crohn’s, IBD H3K4me1 0.44 9.96 -1.59 -2.62 EIF3CL 15Quies 4
1 rs57126490 UC, MS, RA, IBD DHS 0.43 4.65 -0.14 0.04 PANK4 5TxWk 0
6 rs915654 UC, SLE, Crohn’s, PBC, MS, RA,
IBD
H3K4me3 0.42 3.48 5.98 3.51 LTA 7Enh 5
1 rs114312440 Crohn’s H3K4me3 0.41 -4.54 3.44 -2.79 MTX1 5TxWk 2
3 rs71155551 SLE H3K27ac 0.39 4.73 3.20 1.27 COPG1 5TxWk 2
1 rs34769708 Crohn’s H3K4me3 0.39 -4.86 2.13 -2.71 ASH1L 7Enh 3
6 rs13197384 MS H3K4me3 0.35 6.68 4.44 3.84 AHI1 1TssA 16
6 rs147085011 UC, SLE, PBC, MS, RA, IBD H3K4me3 0.32 5.11 -0.27 -0.42 RPP21 1TssA 16
16 rs243332 PBC, MS DHS 0.28 4.45 2.26 0.74 SOCS1 1TssA 9
6 rs575034 RA H3K4me1 0.23 3.73 3.51 0.85 SLC35B2 1TssA 1
2 rs737231 Crohn’s, Celiac H3K4me1 0.22 3.59 3.13 2.10 SLC9A4 15Quies 6
5 rs17097187 MS H3K4me3 0.22 -2.94 6.27 -4.93 PCDHGA1 9Het 4
2 rs737231 IBD H3K4me1 0.22 3.59 3.13 2.10 SLC9A4 15Quies 6
1 rs2641116 UC, IBD H3K4me3 0.20 4.57 0.59 1.08 PARK7 4Tx 1
20 rs6115319 MS H3K27ac 0.11 -5.58 6.39 -4.13 FAM182B 15Quies 0
https://doi.org/10.1371/journal.pgen.1007240.t004
Methods for fine-mapping with chromatin and expression data
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007240 February 26, 2018 16 / 25
correction will likely further improve the calibration of our method’s credible sets. We note that
pathfinder only uses individuals for which we simultaneously have genetic, chromatin, and
gene expression measurements, thus ignoring eQTL data that has been measured in larger sam-
ple sizes. However, eQTL data from larger samples could potentially be used as a prior for
expectation of SNP causality or perhaps for validation after running pathfinder on real data.
Finally, although our analyses showed that H3K4me3 marks are the most informative for fine-
mapping, small data set sizes analyzed in this work prohibit us in making definitive conclusions
on which mark is most useful leaving such avenues for future work.
Materials and methods
Model and likelihood
For each individual, let h be the signal value for the causal histone mark and G be their vector
of genotypes at a region containing s SNPs. Let E be the individual’s mRNA expression level
for the gene at this region and H be a vector representing all t marks at the region, which con-
tains h. Here we analyze all individual peak locations across all available mark types in a joint
framework. As such, each of t individual marks represents one peak location for a particular
mark type. Our causal framework can be modeled as:
h ¼ Gbg þ g ð1Þ
E ¼ Hbh þ h ð2Þ
where g  N ð0; 1   s2gÞ and h  N ð0; 1   s
2
hÞ. The vector βg represents the allelic effects on
the causal histone mark whose entries will be non-zero only at the causal SNP. The vector βh
represents the histone mark effects on expression levels whose entries will be non-zero only at
the causal histone mark. s2g and s
2
h represent the variance explained at the SNP-mark and
mark-expression levels.
Modeling mark to expression associations. We estimate mark to expression effects with
linear regression to quantify the strength of association of the kth mark through the Wald sta-
tistic:
Zkh ¼
^
b
k
h
SEð ^bkhÞ
ð3Þ
Zkh  N ðl
k
h; 1Þ ð4Þ
l
k
h ¼
b
k
h
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Var ðhkÞ
p
sh
ffiffiffiffi
N
p
ð5Þ
Here,
^
b
k
h is the estimated effect size of the causal peak on expression. l
k
h represents the
strength of our signal for causal marks [19]. However, correlations between histone marks will
induce a non-zero non-centrality parameters (NCPs) at non-causal histone marks. If we collect
all pairwise mark correlations into Sh, and let Λh,d be the vector of NCPs for all histone marks
on expression given causal mark d, all summary statistics can be approximated by an MVN.
ZhjCh  N ðΣhΛh;d;ΣhÞ ð6Þ
where Ch is an indicator vector containing zeros at all non-causal marks and 1 at the causal
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mark d, and ΣhΛh,d represents the vector of induced effect sizes at non-causal marks due to
inter-mark correlations.
As we do not know the causal effect size Λh,d, we use a normal prior on the causal mark
NCPs which can be integrated out as follows:
Λh;djCh; s
2
h  N ð0;ΣC;hÞÞ ð7Þ
ΣC;h ¼ s
2
hDiagðChÞ þ DiagðÞ ð8Þ
ZhjΣh;Ch 
Z
N ðΣhΛh;d;ΣhÞN ð0;ΣC;hÞdΛh;d
 
PðChÞ ð9Þ
¼ N ð0;Σh þ ΣhΣC;hΣhÞPðChÞ ð10Þ
Here the prior probabilities of the causal set vector P(Ch)) is set to be uniform. As a parameter
of the model, we set a prior variance explained s2h for the mark effects. We found the method
to be fairly robust to variations in this parameter (Fig 5J–5L), and chose a prior variance of 5
for our analyses. In practice, we add an  of 0.0001 along the diagonal of SC,h to ensure positive
semidefiniteness. Thus, the mark-expression association statistics can be expressed as:
ZhjCh  N ð0;Σh þ ΣhΣChΣhÞ ð11Þ
Modeling SNP to mark associations. As before, we estimate SNP to mark effects with lin-
ear regression to quantify the strength of association of the jth SNP on the kth mark through
the Wald statistic:
Zj;kg ¼
^
b
j;k
g
SEð ^bj;kg Þ
ð12Þ
Zj;kg  N ðl
j;k
g ; 1Þ ð13Þ
l
j;k
g ¼
b
j;k
g
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Var ðgjÞ
p
sg
ffiffiffiffi
N
p
ð14Þ
Here,
^
b
j;k
g is the estimated effect size of the causal SNP on the causal peak. l
j;k
g , the NCP, rep-
resents the strength of our signal for causal SNP-mark effects. However, LD between SNPs and
correlations between marks will induce non-zero NCPs at non-causal SNP-mark pairs. We
collect all pairwise SNP correlations into Σg and all pairwise mark correlations into Σh, and use
the Matrix-variate Normal distribution to jointly approximate the association statistics for all
SNPs on all marks as:
ZgjCg;Ch MN ðM;Σg;ΣhÞ ð15Þ
Here, M is an s × t matrix representing association means between all s SNPs and all t
marks, where each entryMj;k ¼ Σ
j;c
g Σ
k;d
h lc;d, such that the induced NCP for SNP j on mark k is
just the NCP for causal SNP c on causal mark d, attenuated by the correlation between SNPs j
and c, as well as the correlation between marks k and d. Here, rather than integrating out the
causal NCPs as we did with the mark-expression associations, we use the observed Z-score for
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the causal SNP-mark pair to approximate the λj,k terms, as the integration is not straightfor-
ward in the matrix-variate setting.
Computing posterior probabilities for causality. The posterior probability for causality
for a given path can be expressed as
PðCh;CgjZg;ZhÞ ¼
PðZg;ZhjCh;CgÞPðCh;CgÞ
PðZg;ZhÞ
ð16Þ
A prior can be specified on the probability that a SNP or mark within a fine-mapping region is
causal, informed by features like distance to TSS, which is known to correlate with causality
[10, 21], or functional annotations. Here we assign this prior to be uniform:
PðCh;CgjZg;ZhÞ ¼
PðZg;ZhjCh;CgÞ
PðZg;ZhÞ
ð17Þ
¼
PðZhjChÞðPðZgjCh;CgÞ
PðZg;ZhÞ
ð18Þ
We obtain P(Zh|Ch) from Eq 11 and P(Zg|Ch, Cg) from Eq 15. We then compute P(Zg, Zh) by
summing over the individual likelihoods for all possible causal paths. Here our method
assumes a single causal SNP and mark per region, as we restrict our enumeration to only pair-
wise causal SNP-mark combinations.
Simulation framework
We simulated data for 100 individuals over 10,000 50KB regions, using genotypes and LD
from 65 YRI individuals obtained through 1000 Genomes [26]. SNP and mark correlations in
our simulations were taken from the true correlations exhibited in these regions derived from
these individuals. To determine causal status, we randomly chose one SNP and one mark to be
causal in each region, thus defining a causal path through the data. Subsequently, we standard-
ized genotypes and simulated values for chromatin marks and gene expression over all 100
individuals.
In order to simulate correlations between histone marks as observed in our empirical
data, we drew mark values from an MVN as N ðHind; gShÞ, where the means, Hind = HcSh,c,
represent the induced values on non-causal marks due to correlations with the causal mark.
The mean mark values for the causal mark were generated for each of the 100 individuals as
Hc = βgGc, where Gc is the genotype of the individual at the causal SNP, the effect size βg was
drawn from a normal distribution, N ð0; s2gÞ, with variance set to the desired variance
explained by SNPs on marks s2g ¼ 0:25, with the error term g set to 1   s
2
g . Finally, the indi-
viduals’ values for gene expression are computed as E = βhHc + h, where Hc is the causal
mark value as computed from the MVN, the effect size βh was set to the desired variance
explained from mark to expression s2g ¼ 0:25, with the remaining error term given by
N ð0; 1   s2gÞ.
For simulations in which there were multiple causal SNPs or marks, we randomly drew m
or p, the number of causal SNPs or marks, from a binomial distribution where the expected
number of causals per region was set to 1. However, we only included simulations with two or
more causals. For multi-causal-SNP simulations, we then randomly selected m causal SNPs in
the region and simulated chromatin marks and gene expression as described previously,
but drew the effect sizes of each SNP as N ð0; s2g=mÞ, such that the total expected variance
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explained remained at 0.25. For multi-causal-mark simulations, we randomly selected p causal
marks in the region and simulated chromatin marks by defining the means, Hc, of each causal
mark independently as described for the single-causal simulations. We then computed gene
expression by drawing the effect size, βh, of each causal mark from N ð0; s2g=pÞ such that the
total expected variance explained remained at 0.25.
Existing approaches
We benchmark our method against five alternative approaches. Firstly, we compare against
the standard overlap analysis whereby hQTLs and eQTLs are independently identified within
a region centered around a gene. We follow the protocol outlined in [14]. In this experiment,
we computed the best SNP association in each region with every mark measured in the region
as well as with the gene expression value for that region. We determined adjusted p-values for
each top association by performing permutation tests. We then accounted for multiple testing
at the mark level by determining the minimum FDR at which each adjusted p-value would be
considered significant. This was estimated via the qvalue package [27]. This procedure resulted
in a set of significant SNP-mark associations, as well as one SNP-expression association within
the region, as only the top SNP association is retained for each biological phenotype. We then
evaluated the number of causal SNPs, marks, and paths that were ultimately included in these
candidate sets.
Secondly, we compared against the approach of independently fine-mapping the two levels
of data (SNP-mark and mark-expression), and multiplying together pairs of posterior proba-
bilities to produce probabilities of causality for paths. For these independent fine-mapping
experiments, we used a simple approach that assumes a single causal variant, approximating
posterior probabilities for causality directly from Z-scores [28].
In addition, we compared against a basic ranking approach, where we independently com-
puted SNP-mark, mark-expression, and SNP-expression associations for every SNP and mark
within a region. For SNP and mark prioritization, we simply produced a ranking of the SNP-
expression and mark-expression posterior probabilities for causality, respectively. For path pri-
oritization, we produced a ranking of the product of SNP-mark and SNP-expression posterior
probabilities.
We next compared against a bayesian network model which computes directed association
strengths between all possible pairs of nodes in a given network [20]. The method takes as
input raw genotype and phenotype values. As nodes, we included all SNPs and marks, as well
as the gene expression value, within a region. We allowed only for node pairings directed from
SNP to mark or from mark to gene expression. For SNP and mark prioritization, we ranked
association strengths over all directed SNP-expression edges and mark-expression edges,
respectively. For path prioritization, we produced a ranking of the product of SNP-mark and
mark-expression strengths.
Finally, we compared against Coloc, which is designed to identify SNPs that are likely to
be causal for multiple traits at once. Specifically, Coloc outputs a posterior probability that a
SNP is causal for two arbitrary traits simultaneously. We adapted Coloc for our purposes by
running the method on all SNPs independently. For each SNP, the two given traits were (1)
gene expression, and (2) a mark value. Thus, we ran Coloc independently for all SNP-mark
combinations. This produced a set of posterior probabilities indicating, for each SNP-mark
combination, the likelihood that the SNP is causal for both the mark value and gene expres-
sion simultaneously. For path prioritization, we ranked these probabilities over all SNP and
mark combinations. For SNP and mark prioritization, we marginalized over all marks and
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SNPs, respectively, producing posterior probabilities for each SNP and mark to be causal
independently.
Real data
The real data analyses were done on 65 YRI individuals whose genotypes were obtained
through 1000 Genomes and standardized. PEER-normalized [29] H3K4me1, H3K4me3,
H3K27ac, DHS, and RNA expression marks in lymphoblastoid cell lines (LCLs) for these indi-
viduals were obtained from [10]. For each gene in the dataset, we computed associations for
every SNP-mark, SNP-gene, and mark-gene pair within a 50kb window centered around the
gene TSS. On average, each region contained 160 SNPs and 25 marks (across the four mark
types—H3K4me1, H3K4me3, H3K27ac, and DHS—whose peak values we analyzed together
in each region). Overall, from 14,669 50kb regions, we filtered for regions that exhibited evi-
dence for our sequential model where SNPs affect chromatin marks, which in turn affect gene
expression. Specifically, for each region we performed a two-stage regression where we first
regressed gene expression on all chromatin marks, and (2) regressed the proportion of expres-
sion explained by the chromatin marks on each SNP. If at least one SNP had a low p-value for
association (p< 0.05/n.snps) to the proportion of gene expression explained by chromatin
data, we kept this region for our real data analysis. After this filtering procedure, we retained
1,317 regions.
We obtained motif annotations from HaploReg [25] and ChromHMM annotations from
the NIH Roadmap Epigenomics Consortium [30]. When comparing annotations of top priori-
tized paths with those of random paths, we established corresponding background paths by
choosing a random SNP/mark combination at every region where a top path was reported.
For GWAS analyses, we explored regions whose tag SNP was associated to an autoimmune
trait with p< 5 × 10−8. Associations were obtained from recent literature for eight autoim-
mune phenotypes [31–36]. For each of pathfinder’s top reported paths, we determined whether
the corresponding SNP was contained within any of the GWAS regions in our dataset. In
order establish a null distribution for this statistic, we ran the same analysis for random regions
in the genome not overlapping with the GWAS regions in our dataset. Specifically, for each
GWAS region, we randomly selected a SNP in the same chromosome matched for MAF
( = 0.01) and LD score ( = 0.001) with the GWAS tag SNP. We established a window around
this matched SNP corresponding to the window size of the GWAS region. Finally, we deter-
mined the number of top paths that fell within these random regions. We repeated this experi-
ment 100 times to establish the null distribution of this measurement and calculated a p-value
using a Z-test.
Supporting information
S1 Table. 50%, 90%, and 99% credible sets for SNP-, mark-, and path-mapping in simula-
tions. We compare pathfinder to basic eQTL mapping with respect to the size of their credible
sets, averaged across all regions. Standard errors are included next to each measurement.
(TIF)
S2 Table. 50%, 90%, and 99% credible sets for SNP-, mark-, and path-mapping for simula-
tions using YRI LD and CEU LD. We compare pathfinder’s performance on simulations
using SNP LD from YRI versus from CEU, with respect to the size of its credible sets, averaged
across all regions. Standard errors are included next to each measurement.
(TIF)
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S3 Table. Aggregate probability mass assigned to DHS, H3K4me1, H3K4me3, and
H3K27ac. We compare the total probability amassed at all peaks for each mark type after run-
ning pathfinder on empirical data. We display both the raw probability mass and the average
mass contribution per peak location for each mark type.
(TIF)
S4 Table. 50%, 90%, and 99% credible sets for SNP-, mark-, and path-mapping for real
data analysis in CEU individuals. We compare pathfinder’s performance on PEER-corrected
data and raw data, with respect to the size of its credible sets, averaged across all regions. Stan-
dard errors are included next to each measurement.
(TIF)
S1 Fig. 50%, 90%, and 99% credible sets for SNP-, mark-, and path-mapping, in compari-
son to independent fine-mapping. We compare pathfinder to the technique of independently
fine-mapping the two levels of data, with respect to the calibration of their credible sets (A, C,
E) and the size of their credible sets (B, D, F).
(TIF)
S2 Fig. Performance of the method in the presence of two anti-correlated mark effects. We
assess pathfinder’s behavior in simulations with respect to SNP-, mark-, and path-mapping
(A-C) when an additional peak in the region has an effect on expression that is opposite from
the mediating peak in question, compared with regions in which the effect of the additional
peak has a matching sign.
(TIF)
S3 Fig. Comparison of ranking approaches in response to violations of the causal model.
We compare pathfinder’s response to violations of the causal model against the behavior of
other ranking approaches. Causal models are illustrated to the left of the figure. (A, D, G, J, M,
P, S) display SNP-mapping accuracy. (B, E, H, K, N, Q, T) display mark-mapping accuracy.
(C, F, I, L, O, R, U) display path-mapping accuracy.
(TIF)
S4 Fig. Runtime analysis. pathfinder’s runtimes on empirical data with respect to the number
of SNPs, marks, and paths within a region (A-C). We plot each simulation as a point and fit a
line to all points.
(TIF)
S5 Fig. Observed h2g in empirical data. We report the distribution of SNP-mark (A), mark-
expression (B), and SNP-expression (C) h2g levels observed across all top paths selected by path-
finder.
(TIF)
S6 Fig. Association plots for top region reported by pathfinder in real data, spanning a
50kb region centered around the NDUFA12 TSS. (A) Mark-expression Z-scores are reported
for all marks. (B) SNP-mark Z-scores are reported for the top mark chosen by pathfinder. The
implicated SNP, rs835044, lies 6bp downstream of the NDUFA12 TSS.
(TIF)
S7 Fig. Spatial relationships between SNP, mark, and TSS in top paths reported by path-
finder vs random paths, stratified by mark type. (A-C) DHS. (D-F) H3K4me1. (G-I)
H3K4me3. (J-L) H3K27ac.
(TIF)
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